HeartMate 3左心室辅助装置上市后经验:ELEVATE注册研究30天结局
ELEVATE注册研究为前瞻性、观察性、多国注册研究,纳入CE认证后接受HeartMate 3左心室辅助装置的患者,并与CE Mark临床试验患者比较手术结局。结果显示ELEVATE组患者病情更重(INTERMACS 1-2比例32% vs 10%,p<0.001),但调整基线后30天生存率相当(95% vs 98%,p=0.46),且心律失常发生率更低(13% vs 28%,p=0.009),30天内无泵血栓病例。
要点
- ELEVATE注册组患者病情更重,但30天生存率与CE Mark试验组相当。
- ELEVATE组心律失常发生率显著低于CE Mark试验组。
- 植入技术已发展为更灵活的方式,包括微创和非体外循环植入。
核心结论
- 尽管ELEVATE注册组患者病情更重,其30天结局与CE Mark试验组相当。
- 不良事件发生率保持较低,30天内无泵血栓病例。
- 植入技术已演变为包括更灵活的方法,如微创和非体外循环植入。
研究设计与样本
- 前瞻性、观察性、多国ELEVATE注册研究,纳入CE认证后接受HeartMate 3的患者,并与CE Mark临床试验患者比较。
- ELEVATE注册组N=463,CE Mark试验组N=50。
主要发现
- ELEVATE组INTERMACS 1-2比例32%,CE Mark组10%(p<0.001)。
- 调整基线特征后,30天生存率ELEVATE组95%,CE Mark组98%(p=0.46)。
- ELEVATE组心律失常发生率13%,CE Mark组28%(p=0.009)。
- ICU住院时间ELEVATE组7天,CE Mark组6天。
临床怎么用
- 在病情更重的患者中,HeartMate 3仍可取得与临床试验相当的30天生存率。
- 随着经验积累,可采用微创和非体外循环等更灵活的植入技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HeartMate 3 left ventricular assist device (Abbott, Chicago, IL) is designed to provide circulatory support with enhanced hemocompatibility for patients with advanced heart failure. The purpose of this study was to compare the surgical outcomes between patients treated during the European Conformity Mark (CE Mark [CEM]) clinical trial and those treated in the postmarket era. METHODS: The prospective, observational, multinational ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) registry includes patients receiving the HeartMate 3 following CEM approval. Outcomes of patients in the ELEVATE registry are compared with patients in the CEM trial. RESULTS: Compared with the CEM trial (N = 50), the ELEVATE registry group (N = 463) was more severely ill, with more patients classified as INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 1 to 2 (32% versus 10%; p < 0.001). The CEM trial group was younger and underwent fewer concomitant valve procedures. After adjustment for differences in baseline characteristics, the 30-day survival was comparable between the ELEVATE registry and CEM trial groups (95% versus 98%; p = 0.46). Length of intensive care unit stay was similar between the ELEVATE registry (7 days) and CEM trial (6 days) groups. Most adverse event rates were comparable between the 2 groups. ELEVATE registry patients had a lower rate of cardiac arrhythmias (13% versus 28%; p = 0.009). With increasing experience, the implant technique has evolved to include more versatile approaches such as less invasive and off-pump implantation. CONCLUSIONS: The 30-day outcomes for ELEVATE registry patients are comparable despite being sicker than CEM trial patients. Adverse event rates remain low, with no cases of pump thrombosis within the first 30 days. Implant techniques have evolved to include more versatile approaches.
引用
- Garbade J, Gustafsson F, Shaw S, et al. Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry. Ann Thorac Surg. 2018. PMID: 30291831. doi:10.1016/j.athoracsur.2018.07.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。